Literature DB >> 22621210

Effect of prolonged oral acyclovir treatment in acute retinal necrosis.

Sohee Jeon1, Hirohiko Kakizaki, Won Ki Lee, Donghyun Jee.   

Abstract

BACKGROUND: To examine the effectiveness of prolonged oral acyclovir treatment in patients with acute retinal necrosis (ARN).
METHODS: Fifty-five ARN patients (62 eyes) who had been treated with short-term or long-term oral acyclovir were identified in this retrospective study: one group treated with prolonged oral acyclovir (≥14 weeks) and the other group treated with a shorter duration of oral acyclovir (<14 weeks). The authors examined whether the prolonged treatment reduced the involvement of the contralateral eye. They also evaluated prognostic factors for visual outcome.
RESULTS: Prolonged oral acyclovir treatment reduced the involvement of the contralateral eye (p = .036). The visual outcome was influenced by the timing of treatment initiation after symptom onset (p = .030), the age of the patient (p = .027), the area of retinal disease (p = .026), and the retinal detachment (p = .002).
CONCLUSIONS: Prolonged oral acyclovir treatment had a significant role in preventing the involvement of the contralateral eye.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621210     DOI: 10.3109/09273948.2012.689073

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  3 in total

1.  Recurrence of acute lymphoblastic leukemia manifesting as serous retinal detachments and optic disc swelling.

Authors:  Ozge Yabas Kiziloglu; Mert Mestanoglu; Ozgun Melike Totuk Gedar; Cafer Adiguzel; Okan Toygar
Journal:  Int Ophthalmol       Date:  2017-07-15       Impact factor: 2.031

Review 2.  Advances in the management of acute retinal necrosis.

Authors:  Jessica G Shantha; Heather M Weissman; Matthew R Debiec; Thomas A Albini; Steven Yeh
Journal:  Int Ophthalmol Clin       Date:  2015

3.  Herpes zoster keratitis development after acute retinal necrosis.

Authors:  Waseem H Ansari; Francesco Pichi; Paula E Pecen; Careen Y Lowder; Sunil K Srivistava
Journal:  Int Ophthalmol       Date:  2017-04-22       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.